Urothelial Carcinoma
First-line combination demonstrates durable benefit in advanced urothelial carcinoma
CHICAGO — First-line enfortumab vedotin-ejfv plus pembrolizumab conferred promising long-term outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma, study results presented at ASCO Annual Meeting showed.
FDA grants Padcev with Keytruda accelerated approval for advanced urothelial carcinoma
The FDA granted accelerated approval to the combination of enfortumab vedotin-ejfv and pembrolizumab as first-line treatment for cisplatin-ineligible adults with locally advanced or metastatic urothelial carcinoma.
Atezolizumab may benefit some patients with metastatic urothelial carcinoma, high PD-L1 expression
SAN FRANCISCO — Atezolizumab monotherapy improved OS compared with chemotherapy among patients with PD-L1-high, cisplatin-ineligible metastatic urothelial carcinoma, according to an exploratory analysis of a randomized phase 3 study.
Findings from negative urothelial carcinoma trial suggest ‘chemotherapy backbone matters’
SAN FRANCISCO — The addition of atezolizumab to platinum-based chemotherapy failed to significantly improve survival for patients with metastatic urothelial carcinoma, according to a final analysis of the randomized phase 3 IMvigor130 trial.
Adjuvant nivolumab improves outcomes in high-risk urothelial cancer
SAN FRANCISCO — Adjuvant nivolumab improved outcomes compared with placebo for patients with high-risk muscle-invasive urothelial carcinoma, according to study results.
Biomarkers may predict outcomes with enfortumab vedotin for advanced urothelial carcinoma
SAN FRANCISCO — Several potential genetic biomarkers may predict how patients with advanced urothelial carcinoma will respond to enfortumab vedotin, according to retrospective study results.
Sacituzumab govitecan induces response in cisplatin-ineligible urothelial carcinoma
SAN FRANCISCO — Sacituzumab govitecan induced response among one-third of platinum-ineligible patients with metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy, according to study results.
Roche withdraws atezolizumab indication for urothelial carcinoma
Roche voluntarily withdrew atezolizumab’s indication in the United States for the treatment of adults with locally advanced or metastatic urothelial carcinoma.
Bone metastases in bladder cancer predict worse outcomes
CHICAGO — Patients with bone metastases due to urothelial carcinoma had worse outcomes than those without bone metastasis, regardless of treatment or PD-L1 expression, according to a poster presentation at ASCO Annual Meeting.